Takeda Pharmaceuticals Australia has notified us that due to the increase in demand for other strengths, Vyvanse (lisdexamfetamine dimesilate) 40 mg will be in shortage in Australia from 22 January 2024 until 30 April 2024.
We have approved the supply of overseas-registered alternatives to Vyvanse 30 mg, 50 mg and 60 mg under section 19A of the Therapeutic Goods Act 1989. Up-to-date information about these products is available on the Section 19A approvals database.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.